Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
Study sponsor: Allarity Therapeutics
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2021-10-01Actual
Enrollment · participants15Actual
Source updated2025-01-23Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.